Last reviewed · How we verify

Bevacizumab Biosimilar IBI305 plus sintilimab

Ze-yang Ding, MD · Phase 2 active Small molecule

Bevacizumab Biosimilar IBI305 plus sintilimab is a PD-1 inhibitor and anti-VEGF monoclonal antibody Small molecule drug developed by Ze-yang Ding, MD. It is currently in Phase 2 development for Non-small cell lung cancer, Colorectal cancer. Also known as: Byvasda (B) plus S.

Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction. Used for Non-small cell lung cancer, Colorectal cancer.

At a glance

Generic nameBevacizumab Biosimilar IBI305 plus sintilimab
Also known asByvasda (B) plus S
SponsorZe-yang Ding, MD
Drug classPD-1 inhibitor and anti-VEGF monoclonal antibody
TargetPD-1 and VEGF-A
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

Bevacizumab Biosimilar IBI305 works by binding to VEGF-A, preventing its interaction with its receptor and thereby inhibiting angiogenesis. Sintilimab, on the other hand, binds to PD-1, preventing its interaction with PD-L1 and thereby enhancing T-cell activation and anti-tumor immune response.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Bevacizumab Biosimilar IBI305 plus sintilimab

What is Bevacizumab Biosimilar IBI305 plus sintilimab?

Bevacizumab Biosimilar IBI305 plus sintilimab is a PD-1 inhibitor and anti-VEGF monoclonal antibody drug developed by Ze-yang Ding, MD, indicated for Non-small cell lung cancer, Colorectal cancer.

How does Bevacizumab Biosimilar IBI305 plus sintilimab work?

Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.

What is Bevacizumab Biosimilar IBI305 plus sintilimab used for?

Bevacizumab Biosimilar IBI305 plus sintilimab is indicated for Non-small cell lung cancer, Colorectal cancer.

Who makes Bevacizumab Biosimilar IBI305 plus sintilimab?

Bevacizumab Biosimilar IBI305 plus sintilimab is developed by Ze-yang Ding, MD (see full Ze-yang Ding, MD pipeline at /company/ze-yang-ding-md).

Is Bevacizumab Biosimilar IBI305 plus sintilimab also known as anything else?

Bevacizumab Biosimilar IBI305 plus sintilimab is also known as Byvasda (B) plus S.

What drug class is Bevacizumab Biosimilar IBI305 plus sintilimab in?

Bevacizumab Biosimilar IBI305 plus sintilimab belongs to the PD-1 inhibitor and anti-VEGF monoclonal antibody class. See all PD-1 inhibitor and anti-VEGF monoclonal antibody drugs at /class/pd-1-inhibitor-and-anti-vegf-monoclonal-antibody.

What development phase is Bevacizumab Biosimilar IBI305 plus sintilimab in?

Bevacizumab Biosimilar IBI305 plus sintilimab is in Phase 2.

What are the side effects of Bevacizumab Biosimilar IBI305 plus sintilimab?

Common side effects of Bevacizumab Biosimilar IBI305 plus sintilimab include Hypertension, Fatigue, Diarrhea.

What does Bevacizumab Biosimilar IBI305 plus sintilimab target?

Bevacizumab Biosimilar IBI305 plus sintilimab targets PD-1 and VEGF-A and is a PD-1 inhibitor and anti-VEGF monoclonal antibody.

Related